UA102257C2 - Офтальмологічний водний розчин для лікування очної гіпертензії та глаукоми - Google Patents

Офтальмологічний водний розчин для лікування очної гіпертензії та глаукоми

Info

Publication number
UA102257C2
UA102257C2 UAA201015619A UAA201015619A UA102257C2 UA 102257 C2 UA102257 C2 UA 102257C2 UA A201015619 A UAA201015619 A UA A201015619A UA A201015619 A UAA201015619 A UA A201015619A UA 102257 C2 UA102257 C2 UA 102257C2
Authority
UA
Ukraine
Prior art keywords
glaucoma
ocular hypertension
aqueous composition
treating ocular
ophthalmic aqueous
Prior art date
Application number
UAA201015619A
Other languages
English (en)
Russian (ru)
Inventor
Тімо Реунамакі
Пертті Пеллінен
Оллі Оксала
Карі Лехмуссаарі
Original Assignee
Сантен Фармас'Ютікал Ко., Лтд.
Асахі Гласс Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA102257(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сантен Фармас'Ютікал Ко., Лтд., Асахі Гласс Ко., Лтд. filed Critical Сантен Фармас'Ютікал Ко., Лтд.
Publication of UA102257C2 publication Critical patent/UA102257C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується офтальмологічного водного розчину, який містить: тафлупрост, полісорбат 80, динатрійедетат у визначеному співвідношенні та, факультативно, буферні агенти, агенти для регулювання значення рН та агенти для регулювання ізотонічності, які традиційно застосовують у офтальмологічних розчинах; при цьому розчин по суті не містить консервантів та знаходиться у вмістищі, виготовленому по суті з поліетилену, або контактує з матеріалом вмістища, який складається по суті з поліетилену.
UAA201015619A 2008-05-30 2009-05-28 Офтальмологічний водний розчин для лікування очної гіпертензії та глаукоми UA102257C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
PCT/JP2009/060211 WO2009145356A1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
UA102257C2 true UA102257C2 (uk) 2013-06-25

Family

ID=39940592

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201015619A UA102257C2 (uk) 2008-05-30 2009-05-28 Офтальмологічний водний розчин для лікування очної гіпертензії та глаукоми

Country Status (27)

Country Link
US (3) US9999593B2 (uk)
EP (7) EP2127638A1 (uk)
JP (9) JP2011521943A (uk)
KR (5) KR102114401B1 (uk)
CN (1) CN102083413B (uk)
AR (2) AR071937A1 (uk)
AU (1) AU2009252210C1 (uk)
BR (1) BRPI0913109B8 (uk)
CA (2) CA2965185A1 (uk)
CY (2) CY1115565T1 (uk)
DK (4) DK2772249T3 (uk)
EA (1) EA023661B1 (uk)
ES (5) ES2808050T3 (uk)
GE (1) GEP20156220B (uk)
HR (4) HRP20220361T1 (uk)
HU (3) HUE033103T2 (uk)
JO (1) JO3039B1 (uk)
LT (3) LT2772249T (uk)
MX (1) MX2010012987A (uk)
MY (1) MY159463A (uk)
PL (4) PL2772249T3 (uk)
PT (4) PT2306977E (uk)
SG (1) SG191628A1 (uk)
SI (4) SI3714877T1 (uk)
TW (1) TWI432202B (uk)
UA (1) UA102257C2 (uk)
WO (1) WO2009145356A1 (uk)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
SI3431074T1 (sl) * 2010-07-29 2022-07-29 Allergan, Inc. Raztopine bimatoprosta in timolola brez konzervansov
WO2012015996A2 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free bimatoprost solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
WO2012038469A2 (en) * 2010-09-21 2012-03-29 S&V Technologies Ag Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
CA3050298A1 (en) 2012-08-24 2014-02-27 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
PL3103439T3 (pl) 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
WO2017078953A1 (en) * 2015-11-06 2017-05-11 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
US20190231885A1 (en) 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
CN109843316A (zh) 2016-02-29 2019-06-04 太阳制药全球公司 含有环孢菌素的局部制剂及其用途
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
KR20190128657A (ko) * 2017-03-27 2019-11-18 코와 가부시키가이샤 의약 제제
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3643297A4 (en) 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT
ES2972934T3 (es) * 2017-12-21 2024-06-17 Santen Pharmaceutical Co Ltd Combinación de sepetaprost y ripasudil para su uso en la profilaxis o tratamiento del glaucoma o hipertensión ocular
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
WO2023182480A1 (ja) * 2022-03-25 2023-09-28 株式会社坪田ラボ 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2024203727A1 (ja) * 2023-03-24 2024-10-03 株式会社坪田ラボ 水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
DE69714274T3 (de) 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
KR100489759B1 (ko) 1996-12-09 2005-05-16 바슈 앤드 롬 인코포레이티드 일회용 가요성 컨테이너
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO1999018969A1 (fr) * 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Composition curative de l'hypertension intraoculaire ou du glaucome
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
BR9906597A (pt) 1998-07-14 2000-07-18 Alcon Lab Inc Produto de prostaglandina
JP2003517441A (ja) 1998-09-25 2003-05-27 アルコン ラボラトリーズ， インコーポレイテッド 徐放性で快適な眼疾病用組成物および眼疾病の治療方法
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
EP1312380B1 (en) 2000-06-19 2006-05-03 Santen Pharmaceutical Co., Ltd. Aseptics
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
ATE490761T1 (de) * 2000-09-13 2010-12-15 Santen Pharmaceutical Co Ltd Augentropfen
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
CA2707067C (en) * 2002-09-09 2013-07-16 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1666043B1 (en) 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
CN102526064A (zh) 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
RU2391983C2 (ru) * 2004-12-24 2010-06-20 Сантен Фармасьютикал Ко., Лтд Продукт, содержащий производное простагландина f2 альфа
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
PT1905453E (pt) 2005-07-13 2012-12-04 Santen Pharmaceutical Co Ltd Composição conservante para utilização oftálmica
ES2460967T3 (es) * 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
PL1937212T3 (pl) 2005-10-10 2011-02-28 Santen Sas Emulsje oftalmiczne zawierające prostaglandyny
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
GEP20156220B (en) 2015-01-26
HRP20140979T1 (hr) 2014-11-21
EP4035656A1 (en) 2022-08-03
EP3205334B1 (en) 2020-04-29
SI3714877T1 (sl) 2022-05-31
SG191628A1 (en) 2013-07-31
JP2018154656A (ja) 2018-10-04
JO3039B1 (ar) 2016-09-05
JP6889789B2 (ja) 2021-06-18
HUE049923T2 (hu) 2020-11-30
CY1115565T1 (el) 2017-01-04
ES2627837T8 (es) 2018-02-26
AR071937A1 (es) 2010-07-28
KR101988642B1 (ko) 2019-06-12
HRP20170769T1 (hr) 2017-08-11
JP6356868B2 (ja) 2018-07-11
EP2772249A1 (en) 2014-09-03
ES2968837T3 (es) 2024-05-14
KR102246598B1 (ko) 2021-04-30
HUE033103T2 (en) 2017-11-28
PL2772249T3 (pl) 2017-10-31
KR20190067272A (ko) 2019-06-14
US9999593B2 (en) 2018-06-19
JP6649992B2 (ja) 2020-02-19
WO2009145356A1 (en) 2009-12-03
CY1120351T1 (el) 2019-07-10
PL2306977T3 (pl) 2015-01-30
HRP20220361T1 (hr) 2022-05-13
KR101820816B1 (ko) 2018-01-22
EP3205334A1 (en) 2017-08-16
EA201071413A1 (ru) 2011-06-30
HRP20200998T1 (hr) 2020-10-16
CA2965185A1 (en) 2009-12-03
ES2907982T3 (es) 2022-04-27
US10864159B2 (en) 2020-12-15
LT2772249T (lt) 2017-09-11
DK2772249T3 (en) 2017-07-17
BRPI0913109B1 (pt) 2019-10-22
CN102083413B (zh) 2013-11-06
LT3205334T (lt) 2020-09-25
AU2009252210B2 (en) 2014-10-16
JP2011521943A (ja) 2011-07-28
PT2306977E (pt) 2014-09-22
ES2808050T3 (es) 2021-02-25
KR101650006B1 (ko) 2016-08-22
EP2306977A1 (en) 2011-04-13
JP2023085558A (ja) 2023-06-20
DK2306977T3 (da) 2014-09-15
TW201000104A (en) 2010-01-01
EA023661B1 (ru) 2016-06-30
TWI432202B (zh) 2014-04-01
JP2017178957A (ja) 2017-10-05
PL3714877T3 (pl) 2022-05-16
JP7265584B2 (ja) 2023-04-26
CA2724194A1 (en) 2009-12-03
US20110152264A1 (en) 2011-06-23
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
JP2024079852A (ja) 2024-06-11
SI2772249T1 (sl) 2017-08-31
EP2772249B1 (en) 2017-05-03
KR20110011707A (ko) 2011-02-08
EP3714877A1 (en) 2020-09-30
KR20200057801A (ko) 2020-05-26
ES2495316T3 (es) 2014-09-17
DK3205334T3 (da) 2020-07-13
BRPI0913109A2 (pt) 2017-06-20
KR102114401B1 (ko) 2020-05-25
LT3714877T (lt) 2022-04-11
EP4289446A3 (en) 2024-01-10
US20180289618A1 (en) 2018-10-11
ES2627837T3 (es) 2017-07-31
JP2020073574A (ja) 2020-05-14
MX2010012987A (es) 2011-02-24
BRPI0913109B8 (pt) 2021-05-25
HUE058079T2 (hu) 2022-06-28
AU2009252210A1 (en) 2009-12-03
DK3714877T3 (da) 2022-02-14
JP2016065095A (ja) 2016-04-28
US20210059931A1 (en) 2021-03-04
JP7520285B2 (ja) 2024-07-23
AR120961A2 (es) 2022-04-06
KR20160102319A (ko) 2016-08-29
EP4035656B1 (en) 2023-11-22
EP2127638A1 (en) 2009-12-02
CN102083413A (zh) 2011-06-01
PT3205334T (pt) 2020-07-31
PT3714877T (pt) 2022-03-10
JP6148317B2 (ja) 2017-06-14
MY159463A (en) 2017-01-13
PL3205334T3 (pl) 2020-11-02
PT2772249T (pt) 2017-08-08
EP2306977B1 (en) 2014-08-13
JP2021120412A (ja) 2021-08-19
KR20180008905A (ko) 2018-01-24
EP4289446A2 (en) 2023-12-13
CA2724194C (en) 2017-06-27
JP2014133765A (ja) 2014-07-24
AU2009252210C1 (en) 2016-04-14
EP3714877B1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
UA102257C2 (uk) Офтальмологічний водний розчин для лікування очної гіпертензії та глаукоми
AU2012307812A8 (en) Ophthalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
MX358176B (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
MY175318A (en) Androgen composition for treating an opthalmic condition
MX340957B (es) Composicion oftalmica de alta concentracion de olopatadina.
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
DK2257275T3 (da) Ketorolactromethaminsammensætninger til behandling eller forebyggelse af øjensmerte
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
MY160383A (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
EA201490845A1 (ru) Улучшенная сшивающая композиция, доставляемая способом ионтофореза, пригодная для лечения кератоконуса
BR112012017319A2 (pt) composições e métodos para abaixar a pressão intraocular
MX366526B (es) Una composicion para la preparacion de acido hialuronico reticulado viscoelastico, y acido hialuronico reticulado obtenido al usar la misma.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
WO2010046865A3 (en) Ophthalmic administration of a composition including brimonidine as a mist
MY157434A (en) Method for improving bioavailability of latanoprost
MX2010009814A (es) Compuestos con vitamina d y metodos para reducir la hipertension ocular.
WO2012024419A3 (en) Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
MX2010008308A (es) Tratamiento para trastornos relacionados con los ojos.
MX2011007522A (es) Metodos de tratamiento de la infeccion por el virus del dengue mediante vitamina d.